Aspirin Discontinuation at 24-28 Weeks and Placental Biomarker Trajectories: Post Hoc Analysis of a Randomised Trial.

ABSTRACT:

Objective

To compare the trajectories of placental biomarkers throughout pregnancy after aspirin discontinuation at 24-28 weeks with those of a cohort treated until 36 weeks of gestation.

Design

A longitudinal secondary analysis of the StopPRE trial, using repeated measures of soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), and their ratio.

Setting

Nine maternity hospitals across Spain.

Population

The original StopPRE trial included 936 women at high risk for preterm preeclampsia based on first-trimester screening. All participants received aspirin 150 mg daily until randomisation at 24-28 weeks. At that point, 463 women were assigned to continue aspirin until 36 weeks, while 473 were assigned to discontinue it.

Methods

sFlt-

SUBMITTER: Bonacina E 

PROVIDER: S-EPMC12770070 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature